TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05403866
Drug: LT3001 Drug Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT05403866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT06754475
Drug: Standart medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standart medical teatment
Study: NCT04934059
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5g/ tablet
Study: NCT06749665
Drug: polidacanol 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany
Study: NCT06749054
Drug: Optimized Background Regimen (OBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized background regimen as prescribed by the Investigator
Study: NCT06755515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: placebo Description: iv, every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.
Study: NCT06134713
Drug: cryotherapy with sterile saline at 2.5ºC
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the cryotherapy (experimental group), final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept refrigerated at 2.5ºC and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
Study: NCT06134713
Drug: control with sterile saline at room temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group, final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept at room temperature and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
Study: NCT05977023
Drug: Placebo Cap
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo as a comparator.
Study: NCT06756490
Drug: HY-2003 (10 mg/ml), BELKYRA and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received HY-2003 (10 mg/ml), or BELKYRA, or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments.
Study: NCT06756490
Drug: HY-2003 (5 mg/ml) and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received HY-2003 (5 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
Study: NCT06756490
Drug: HY-2003 (5 mg/ml) and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received HY-2003 (10 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments. It is possible to explore the maximum number of administrations exceeding six treatment sessions.
Study: NCT05228431
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
Study: NCT05228431
Drug: Capecitabine monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
Study: NCT06758557
Drug: HB0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB0025 IV every 3 weeks (q3w)
Study: NCT06757504
Drug: Placebo (Simulant TTYP01 Tablets)
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Study: NCT06757712
Drug: medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medical treatment will be received for 12 weeks.
Study: NCT06757764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)
Study: NCT06759623
Drug: Different drug type for conduction of general anesthesia
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly divided into two groups: patients for whom general anesthesia will be performed with sevoflurane and patients for whom general anesthesia will be performed with desflurane.
Study: NCT06758830
Drug: Consolidation Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX: Oxaliplatin 130 mg/m² (day 1) + capecitabine 1000 mg/m² (days 1-14), every 3 weeks for 4 cycles.~Or FOLFOX: Oxaliplatin - 85 mg/m2 intravenously (2-hour infusion), drip for 1 day. Calcium folinate (folinic acid) - 400 mg/m2/d. intravenously (2-hour infusion), started on day 1. F(5-fluorouracil) - 400 mg/m2/d. intravenously (bolus), started on day 1. Repeat every 2 weeks for 6 times.
Study: NCT06760065
Drug: Susceptibility-Guided Quadruple Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive quadruple therapy tailored to individual H. pylori resistance profiles, including a proton pump inhibitor (Esomeprazole 20 mg), Bismuth Potassium Citrate 220 mg, and two antibiotics selected based on susceptibility testing (e.g., Amoxicillin, Clarithromycin, Metronidazole, Levofloxacin, or Furazolidone). The regimen is administered for 14 days to optimize eradication outcomes.
Study: NCT06759090
Drug: Metronomic capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal;
Study: NCT06760078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous placebo (10mL NS, diluted in 90mL NS) matching the specification and appearance of TXA will be administered as an initial bolus over 10 minutes, followed by a continuous infusion of placebo (10mL NS, diluted in 240mL NS) over 8 hours, with intensive blood pressure lowering maintained throughout the treatment period and continued until 24 hours after symptoms onset.
Study: NCT04631536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
Study: NCT06582485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
Study: NCT06465199
Drug: Difluoromethylornithine (DFMO)
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFMO for IV infusion
Study: NCT06749236
Drug: reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension).
Study: NCT06170216
Drug: immunochemotherapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
Study: NCT06749418
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.
Study: NCT06750432
Drug: PMN310
Approvals — FDA: no, EMA: no, PMDA: no
Description: A humanized immunoglobulin G1 (IgG1) monoclonal antibody
Study: NCT06750432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl 100 mL
Study: NCT06456580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT06427850
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive an injection of Normal saline into the surgical site
Study: NCT05134363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: equal volume of normal saline
Study: NCT06221826
Drug: Mexidol
Normalized name: Brexidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocytoprotector
Study: NCT04940624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat placebo-matching mini-tablets or tablets.
Study: NCT06253806
Drug: Placebo Sham Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 0.9% saline will be injected near the stellate ganglion.
Study: NCT06625957
Drug: NTCB02-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Days infusion
Study: NCT06625957
Drug: NTCB-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Days infusion
Study: NCT06769620
Drug: ORT247
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORT247 will be provided to study sites in single-use, sterile vials for infusion. Each dose will be prepared with normal saline for infusion.
Study: NCT06769620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consists of normal saline
Study: NCT06759857
Drug: FHND9041
Approvals — FDA: no, EMA: no, PMDA: no
Description: FHND9041 is a novel therapeutic agent targeting EGFR mutations. Participants will take an 80 mg oral dose once daily until disease progression, intolerable toxicity, or meeting other study-defined discontinuation criteria.
Study: NCT06759649
Drug: COM503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT06758596
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A capsule that contains only dextrose filler administered during the first or second laboratory visit.
Study: NCT06762145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 days started from the day on TAVR
Study: NCT06773117
Drug: High dose Susu Xiao'er Zhike Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Susu Xiao'er Zhike Granules 1 bag(7g granule per bag,contains 20.25 g crude herbs), twice a day for five days
Study: NCT06773117
Drug: Extremely-low dose Susu Xiao'er Zhike Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag (7g granule per bag,contains 1.01 g crude herbs), twice a day for five days
Study: NCT05578846
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.
Study: NCT05578846
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
Study: NCT04339036
Drug: Capecitabine Oral Product
Normalized name: capecitabine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 750 mg/m2 twice daily orally for 14 days
Study: NCT05614349
Drug: Other
Normalized name: others
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)
Study: NCT06724640
Drug: VH4011499 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4011499 Injection will be administered either subcutaneously or intramuscularly.
Study: NCT06724640
Drug: Placebo for VH4011499 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for VH4011499 Injection will be administered either subcutaneously or intramuscularly.
Study: NCT06118372
Drug: Recombinant von Willebrand Factor
Normalized name: VON WILLEBRAND FACTOR,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
Study: NCT05596045
Drug: ASC10
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
Study: NCT05596045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive placebo
Study: NCT05717686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT06754371
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of normal saline 20ml 10min before skin dissection
Study: NCT06754761
Drug: [14C] AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiolabeled AZD6738 / ceralasertib
Study: NCT06423703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
Study: NCT06757140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive inactive oral doses
Study: NCT06055231
Drug: Marijuana via vape device
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given via vape device
Study: NCT06055231
Drug: Marijuana via joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given via joint
Study: NCT05262023
Drug: DNL593
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Study: NCT05262023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Study: NCT05708430
Drug: SVF injection into wrist
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
Study: NCT06755242
Drug: GNC-077
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06373653
Drug: Manzanilla Sophia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matricaria recutita 0.025%, Ophthalmic solution.
Study: NCT06373653
Drug: Meticel Ofteno®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypromellose 0.5%, Ophthalmic solution.
Study: NCT05884502
Drug: combination of high-dose rosuvastatin and ezetimibe
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combination of rosuvastatin 20mg and ezetimibe 10mg
Study: NCT05884502
Drug: high-dose rosuvastatin single administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20mg monotherapy
Study: NCT05285813
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth (PO) about 30-60 minutes before the dose
Study: NCT06035978
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
Study: NCT05131828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match both metformin and clemastine tablets.
Study: NCT05799755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05799755
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
Study: NCT04564326
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
Study: NCT05022212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered vaginally
Study: NCT06551233
Drug: 9MW2821
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.
Study: NCT06602479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-matched placebo for all arms
Study: NCT04699279
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
Study: NCT05879627
Drug: BAT8007 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
Study: NCT06041035
Drug: QLS31905
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion.
Study: NCT06041035
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.
Study: NCT06673368
Drug: NRCT-101SR, NRCT-202XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRCT-101SR in combination with NRCT-202XR or NRCT-202XR alone
Study: NCT05335317
Drug: Topical hormone estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
Study: NCT06374485
Drug: AU409 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05774964
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/time, qd
Study: NCT06767007
Drug: PD1
Normalized name: STATLOCK UNIVERSAL PLUS LG VUPD1214
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PD-1 monoclonal antibody used is Sintilimab 200mg every 3 weeks
Study: NCT06767007
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line chemotherapy regimen of rectal cancer, using a second-line regimen primarily based on fluorouracil, such as a tri-weekly CAPOX or a bi-weekly mFOLFOX6/FOLFIRI/FOLFOXIRI + targeted therapy
Study: NCT06454747
Drug: SM-030 gel 0.64%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application to face twice daily for 12 weeks.
Study: NCT06097767
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
Study: NCT06097767
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group
Study: NCT06765668
Drug: CREXONT ER
Normalized name: carbidopa / levodopa Extended Release Oral Capsule [Crexont]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CREXONT ER capsule.
Study: NCT06764680
Drug: Trifluorouracil tepidopyrimidine
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w
Study: NCT05743010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules orally once daily
Study: NCT04759807
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
Study: NCT04759807
Drug: PUR1800 250 ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
Study: NCT04759807
Drug: PUR1800 500 ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
Study: NCT06764147
Drug: ET-26HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
Study: NCT06790927
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doctor prescribes medication for patients and follow-up every 3 months
Study: NCT06454747
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application to face twice daily for 12 weeks.
Study: NCT06101160
Drug: onaBoNT-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection under ultrasonography